Search

Your search keyword '"Rossotti, Roberto"' showing total 185 results

Search Constraints

Start Over You searched for: Author "Rossotti, Roberto" Remove constraint Author: "Rossotti, Roberto" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
185 results on '"Rossotti, Roberto"'

Search Results

4. Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona)

5. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy

6. FRI-442 Disease progression and persistent alanine aminotransferase elevation in HCV/HIV persons after DAA-related eradication: role of HBV and HDV co-infections

7. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy

9. Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort

10. Surge of Mpox cases in Lombardy region, Italy, October 2023 - January 2024

11. Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition

12. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy

13. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir‐based dual combinations.

14. Performance evaluation of a self-administered point of-care test for anal HPV screening in PrEP users: data from a community-based PrEP service.

16. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

20. Detection of Asymptomatic Mpox Carriers among High-Ri Men Who Have Sex with Men: A Prospective Analysis

21. HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network

23. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection

24. Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.

25. Impact of treatment with direct‐acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co‐infected individuals

26. Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation

32. HIV‐NAAT use for early detection of HIV infection among high‐risk men who have sex with men in Italy

36. Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy

39. Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients

41. Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience

42. Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection

44. Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy

45. Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy

46. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

47. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients

48. Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience

49. HIV/HCV co-infected subjects show better thrombocytopenia improvement after sustained virologic response achievement than HCV mono-infected cirrhotics. Data from the hepaiCONA and PITER cohorts.

50. Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort

Catalog

Books, media, physical & digital resources